POS1340 BASELINE CLINICAL DISEASE ACTIVITY IS NOT CRITICAL FOR PREDICTING REMISSION OF ADULTS ONSET STILL´S DISEASE

Background The clinical course of adult-onset Still’s disease (AoSD) is highly variable, ranging from subtle constitutional symptoms to life-threatening complications such as macrophage activation syndrome. Therefore, it interest whether baseline activity in AoSD predicts the course, i.e. and serological remission. Objectives aim this study was compare two instruments measure activity, Pouchot-Score Still-Activity-Score (SAS), at predict later remission disease. We also assessed serum levels calprotectin (S100A8/A9) are associated with measured by SAS follow up. Methods diagnosed according Yamaguchi criteria. In all patients Still-Activity Score (SAS) were score follow-up. Clinical defined absence (i.e. fever arthralgia), while normalization Ferritin, IL-18 S100A8/A9 (calprotectin) levels. To investigate prediction accuracy for remission, a calculation areas under receiver operating characteristic (ROC) curves performed. Results 42 (19 males/23 females; mean+/-SD age:41+/-17 years) assessed. Baseline 5.3 +/- 1.6, 5.7 1.0. With treatment AoSD, decreased reaching mean 2.2 1.8 after up time 48 90 months. Glucocorticoids used 33%, methotrexate 21%, IL-1 inhibitors 33% IL-6 29% patients. 62% (N=26) obtained 36% (N=15) Neither (0.57) nor (0.51) predicted AoSD. Furthermore, not (0.62) or (0.56) (Figure 1). respect during closely (r = 0.54, p < 0.0003) 2). Conclusion does Serum level related phase. Figure 1. ROC 2. Association between protein ELISA method follow-up Acknowledgements research project supported SOBI Novartis. Disclosure Interests Jennifer Groetsch: None declared, Koray Tascilar: Georg Schett: Dirk Foell: Jürgen Rech Speakers bureau: Abbvie, Biogen, BMS, Chugai, GSK, Lilly, MSD; Novartis, Roche, Sanofi, Sobi, UCB, Consultant of: MSD, Grant/research support from: Novartis